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The viral envelope glycoprotein D from bovine herpesviruses 1 and 5 (BoHV-1 and -5), two important pathogens of
cattle, is a major component of the virion and plays a critical role in the pathogenesis of herpesviruses. Glycoprotein
D is essential for virus penetration into permissive cells and thus is a major target for virus neutralizing antibodies
during infection. In view of its role in the induction of protective immunity, gD has been tested in new vaccine
development strategies against both viruses. Subunit, DNA and vectored vaccine candidates have been developed
using this glycoprotein as the primary antigen, demonstrating that gD has the capacity to induce robust virus
neutralizing antibodies and strong cell-mediated immune responses, as well as protection from clinical symptoms,
in target species. This review highlights the structural and functional characteristics of BoHV-1, BoHV-5 and where
appropriate, Human herpesvirus gD, as well as its role in viral entry and interactions with host cell receptors.
Furthermore, the interactions of gD with the host immune system are discussed. Finally, the application of this
glycoprotein in new vaccine design is reviewed, taking its structural and functional characteristics into consideration.Table of contents
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Herpesviruses constitute a large and diverse family of
enveloped viruses and are composed of three subfamilies,
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article, unless otherwise stated.classified in the Alphaherpesvirinae subfamily share sev-
eral characteristics including a rapid reproductive cycle
and, at least for three genera of this subfamily, the ability
of neuronal invasion and establishment of latency in sen-
sory nerve ganglia (reviewed by Engels and Ackermann in
1996 [1]). Important prototypes of this family comprise
human herpesviruses, such as Human herpesvirus (HHV)-
1 and -2 (known as herpes simplex virus (HSV)-1 and -2),
and animal herpesviruses. Among alphaherpesviruses in-
fecting ruminants, the prototype is Bovine herpesvirus 1
(BoHV-1); however, the closely related BoHV-5 is also of
great importance in veterinary medicine [2].
BoHV-1 is a pathogen of cattle associated with two
major syndromes, called infectious bovine rhinotrachei-
tis (IBR) and infectious pustular vulvovaginitis (IPV) [1].
It is one of the pathogens involved in the bovine respira-
tory disease complex (BRD), also referred to as “shipping
fever”, which economically affects producers by reducing
the average daily weight gain, feed efficiency, and overall
performance of calves (reviewed in reference [3]). The
severe damage that exposure to BoHV-1 can cause to
the respiratory tract creates opportunities for further
fatal secondary bacterial infections [4,5].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sites as BoHV-1, i.e. nasal cavity, eyes, oropharynx and
genital tract. The first round of replication usually takes
place in the epithelial cells at these entry sites, and then
the virus can spread to the neurons [6]. Although
BoHV-5 and BoHV-1 are genetically and antigenically
related, sharing on average 82% of identity in their
amino acid sequences [7], they differ in their neuroinva-
sion and neurovirulence ability. Neuroinvasion of
BoHV-1 usually does not progress beyond the first order
neuron located in the trigeminal ganglion, where the la-
tent infection is established, whereas BoHV-5 can infect
different regions of the brain causing lethal encephalitis
in young animals (reviewed in Zajac et al. [8]).
Vaccination is one of the most cost-effective strategies
to prevent and control the clinical signs and transmission
of these viruses. Conventional modified live and killed vac-
cines have been developed against BoHV-1; however, sev-
eral disadvantages regarding safety and/or efficacy make
then unsuitable for vaccination of some targets such as
pregnant cows (reviewed in reference [9]). New strategies
for vaccine development against both BoHV-1 and BoHV-
5 have been focused on the design of marker vaccines,
which differentiate infected from vaccinated animals (also
known as DIVA vaccines). DIVA vaccines include genetic-
ally engineered gene-deleted viruses, for example gE−
virus, and subunit or vectored vaccines based on a viral
envelope glycoprotein such as gD.
BoHV-1 gE− live marker vaccines have been developed
and tested for virulence in calves, demonstrating protec-
tion after challenge and reduction in virus shedding
without any effect on the immunogenicity of BoHV-1
[10,11]. A gE− live marker vaccine has been used in
eradication programs in countries with a high prevalence
of BoHV-1 infection (reviewed in reference [12]). Field
trials of this vaccine were performed [13] and in 2007, a
study performed in three European countries demon-
strated reduction in the rate of seroconversion observed
in vaccinated animals, suggesting efficiency of the vac-
cination program in containing viral spread [14].
However, the use of a BoHV-1 gE− live marker vaccine
[15] conferred limited protection against encephalitis
when animals were challenged with BoHV-5, with re-
duction in the intensity of the clinical signs after primary
infection, but without protection against infection and
no effect on nasal virus shedding or the development of
encephalitic lesions [16]. Thus, the use of BoHV-1 gE−
live marker vaccine where BoHV-5 prevalence is higher
may be unsuitable. In 2007, Franco et al. [17] reported
the construction of a BoHV-5 gI/gE/US9− and the
resulting virus has been tested as an inactivated vaccine
in 2010 [18], conferring protection to encephalitis after
challenge with a high dose of virulent BoHV-5 and re-
duction of nasal virus shedding in vaccinated animals.Although successful use of BoHV-1 gE− live marker
vaccines has been reported, a number of issues concern-
ing these vaccines have been identified. Contamination
of vaccine batches with bovine viral diarrhea virus
(BVDV) type 2 leading to BVDV outbreaks [19], false
seronegative vaccine virus carriers in calves immunized
while carrying maternal antibodies and latency establish-
ment have been reported [20].
Glycoprotein D (gD), one of the antigens present in
the viral envelope, is involved in virus penetration and
has been considered the major target in vaccine develop-
ment against bovine and human herpesviruses, mainly
owing to its ability to stimulate both humoral and cell-
mediated immune responses in the host (reviewed in
reference [21]). Subunit, DNA and vectored vaccines
based on this glycoprotein have been generated and
evaluated with a variety of adjuvants. This review high-
lights the role of gD in viral pathogenesis and its appli-
cation in vaccine strategies against bovine herpesviruses,
in context of its structural, functional and immuno-
logical properties. In consideration of the molecular
homology between these viruses [7] most of this review
will describe studies with BoHV-1 and BoHV-5. How-
ever, although multiple outbreaks of infection by BoHV-
5 have been described [22-24] and BoHV-5 infection
leads to more serious disease, there are fewer reports on
vaccine development strategies against BoHV-5 than
against BoHV-1 [18,25]. Where appropriate, studies with
gD from other alphaherpesviruses will be described to il-
lustrate the recent progress with gD-based vaccines in
general.
2. Structure of glycoprotein D (gD)
The complex virion structure of the Herpesviridae is
common among the viruses of this family. The virion
consists of a large double-stranded DNA genome pack-
aged into an icosahedral capsid, which, in turn, is sur-
rounded by a layer of proteins called tegument and an
envelope composed of a large number of glycoproteins
embedded in a lipid bilayer (reviewed in reference [26]).
The entry of alphaherpesviruses into permissive cells
is a complex and not yet fully understood process. These
viruses infect cells as free particles and then can spread
to adjacent cells through cell contact. Two mechanisms
have been proposed for this entry: viral envelope fusion
and an endocytic pathway (reviewed in [27,28]). How-
ever, it is known that among the 12 identified envelope
glycoproteins, at least six (gC, gB, gD, gH, gK and gL)
participate in viral attachment and entry. Binding of the
alphaherpesvirus to the host cell is attributed to the re-
versible attachment through gC and/or gB to cell surface
heparan sulfate proteoglycans. A detailed description of
this interaction has been provided in review [29]. Indeed,
the infectivity of alphaherpesviruses is increased when
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also infect the cell [30], suggesting that this attachment
alone is not sufficient for virus penetration and that
more events are required for cell entry. Fusion of the
viral envelope with the plasma membrane of the cell re-
quires the other four glycoproteins (gD, gB and the gH-
gL complex), with the binding of gD to one of its cell
surface receptors being an essential event for herpesvirus
entry, targeting a series of interactions between gB and
gH-gL that occurs concurrently with fusion [31]. An-
other component of the fusion mechanism is gK, which
also interacts with gB by binding to its amino terminus
and modifying the ability of this glycoprotein to mediate
“viral-envelope-to-cellular-membrane fusion” [32]. Al-
though deletion of the gene coding for this protein is
not lethal for replication in cell culture, titers were re-
duced indicating that virions defective in gK have an im-
paired entry process [33].
Glycoprotein D of both BoHV-1 and BoHV-5 consists
of approximately 417 aa, with 79.9% amino acid (aa)
identity [34], N- and O-linked oligosaccharides, and a
molecular weight of approximately 71 kDa [35]. It is a
type I membrane glycoprotein, with a signal sequence
and a cleavage site located between aa 18 and 19 in


















Figure 1 Comparison of the predicted amino acid sequence of gD fro
BoHV-5 gD [GenBank:AAA67359.1] [36] were aligned with Clustal Omega v. 1.
Fully conserved residues are indicated with an asterisk (*); conservation betwe
conservation between groups of weakly similar properties are indicated with
potential N-linked glycosylation sites are indicated with (•). Solid and dashed l
sequences, respectively. An arrow indicates the position of the BoHV-1-gD sigbased on the position, length, relative hydrophobicity
and consensus cleavage site characteristic of a signal se-
quence [36]. This signal sequence is cleaved to yield a
mature protein of 399 aa. The amino-terminal portion
of gD comprises the extracellular domain, while its
carboxy-terminus consists of a hydrophobic transmem-
brane anchor sequence and a cytoplasmic tail of ap-
proximately 28 aa in BoHV-1 gD and 35 aa in BoHV-5
gD [35,37].
The nucleotide sequence of this glycoprotein gene has
a GC nucleotide content of 70% [35], similar to Suid
herpesvirus 1 (SuHV-1) (75%) and HHV-1 (65%) gD ho-
mologues [38]. The BoHV-1 and -5 gD amino acid se-
quence demonstrates conservation of 6 cysteine residues
in its ectodomain, suggesting that these may be disulfide
bond-linked, which probably plays a role in maintaining
the proper 3D-structure and its function [35]. Alignment
of both gDs showed that the amino-terminal two-thirds
(aa 1-282) of BoHV-1 [35,39] and BoHV-5 [36] gD are
relatively well conserved (Figure 1). However, the differ-
ence between gD from these viruses maps to a glycine-
rich stretch located in the molecule’s C-terminal part of
the ectodomain (aa 280 and 330), in close vicinity to the
transmembrane region [34,36]. This region is character-














m BoHV-1 and BoHV-5. BoHV-1 gD [GenBank:CAA80604.1] [39] and
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nal peptide cleavage site (aa 18 and 19) [35].
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with other molecules of the virus, host cell or both
through ionic interactions [37]. This same region in
BoHV-5 gD exhibits several mismatches with the BoHV-
1 gD sequence, with the presence of a series of nega-
tively charged residues from aa 281 to 295 (280 to 292
of BoHV-1 gD), which results in a series of hydrophilic
peaks compared to one broad peak for BoHV-1 gD [36].
Four antigenic domains have been described for
BoHV-1 gD [41], and five epitopes, three interrelated
and two independent, have been reported as targets of
neutralizing antibodies [42]. Monoclonal antibodies de-
veloped to epitopes located between amino acids 52-116
(MAb 3402) and 165-216 (MAb R54) do not recognize
BoHV-5 gD, suggesting that these epitopes are located
in the corresponding altered amino acids in BoHV-5 gD
[36].
The most well characterized homologue is HHV-1 gD,
the ectodomain of which is formed by a core with a
variable-type immunoglobulin fold (IgV) wrapped by a N-
terminal extension and a C-terminal proline-rich exten-
sion [43]. With respect to its glycosylation, differences are
observed in the N-linked oligosaccharide (N-CHO) distri-
bution for gD. HHV-1 and BoHV-1 gD possess three N-
CHO sites (amino acids position 41, 102 and 411 of
BoHV-1 gD), while BoHV-5 gD has only two potential
sites in its sequence, one being located in its cytoplasmic
tail (amino acids 102 and 411 of BoHV-5 gD) [36]. The
importance of the N-CHO sites in gD is attributed to the
influence of glycosylation on the protein structure and
antigenic properties rather than to direct interaction with
cellular receptors [44].
Enzymatic deglycosylation of gD from BoHV-1 sug-
gests that the addition of carbohydrates could mask epi-
topes involved in T cell recognition. This was observed
after injection of native or deglycosylated forms of gD in
rabbits and measurement of the delayed-type hypersen-
sitivity (DTH) response where a stronger DTH reaction
in deglycosylated gD-vaccinated rabbits was observed. In
contrast, the total antibody response to gD after carbo-
hydrate removal was lower than the response observed
for native gD-vaccinated animals; however, the neutraliz-
ing antibody response and the ability of the antibodies to
mediate cell lysis were not significantly reduced, indicat-
ing that most functional epitopes on this glycoprotein
are carbohydrate-independent [44].
To date, three unrelated molecules have been shown to
be gD cell surface receptors: nectin-1, herpesvirus entry
mediator (HVEM) and heparan sulfate modified by 3-O-
sulfotransferases, at least for HHV-1. Nectin-1 (also known
as HveC and Prr1) is the main receptor of gD on epithelial
and neuronal cells [45] and can mediate entry of HHV-1
and -2 as well as SuHV-1 (Pseudorabies virus or PRV),
BoHV-1 and BoHV-5 [46]. However, cells expressingheparin sulfate-modified 3-O-sulfotransferases or the
HVEM receptor are not susceptible to BoHV-1 (reviewed
in 2000 by Spear et al. [47]).
Nectins are homophilic cell adhesion calcium-
independent molecules from the immunoglobulin (Ig)-
like superfamily that accumulate at adherent junctions
of epithelia, at synapses and puncta adherentia of neu-
rons [48,49]. All of the nectins have an ectodomain
comprising three Ig-like domains (V-C1-C2), a trans-
membrane and a cytoplasmic tail region. The gD-
binding region of nectin-1 is localized at the V-like
domain [50]. Studies performed with soluble forms of
gD from HHV-1, HHV-2 and SuHV-1 showed efficient
binding to truncated forms of nectin-1 retaining only
the V-like domain; this binding was blocked by mono-
clonal antibodies specific for epitopes located in this
domain [51,52]. However, a study performed with chi-
meras that combine the V-like domain of nectin-1α
with C-like domains from nectin-2α demonstrates that
the V-like domain is required for full entry activity of
BoHV-1, HHV-1 and -2, and SuHV-1, only when this
domain is linked to two C-domains [53]. Despite the
ability of gD to bind to the V-like domain, attachment
does not result in viral entry, suggesting that binding of
gD induces conformational changes in both gD and the
receptor. This study also suggests that, based on com-
petitive interactions, the regions on nectin-1 to which
gD from different alphaherpesviruses binds, are over-
lapping but not necessarily identical [53].
The function of nectins as adhesion molecules that are
mostly located at cell junctions suggests a key role in
cell-to-cell spread of alphaherpesviruses to neurons of
the peripheral and central nervous systems, as well as in
the epithelium [45,54]. Binding of gD to nectin-1 during
later phases of HHV infection correlates with down-
regulation of nectin-1 in cells susceptible to HHV endo-
cytosis. Co-culture of nectin-1-null cells expressing gD
with target cells that express nectin-1 indicates that the
trans-interaction of gD with nectin-1 at contacts be-
tween the two cell populations led to down-regulation of
nectin-1, consisting of internalization of the receptor
from the target cell surface followed by low-pH-
dependent degradation suggesting a ligand-induced
endocytosis. The cell-bound gD or gD from egressing vi-
rions could then mediate internalization of nectin-1
directing HHV to an endocytic pathway during entry
[45].
Madin Darby bovine kidney (MDBK) cells expressing
gD from BoHV-1 resist infection by heterologous virus,
such as HHV-1 or SuHV-1, a phenomenon termed
interference, which occurs at the level of penetration
into cells [55]. However, these cells are still susceptible
to BoHV-5, demonstrating an absence of interference,
even though the presence of gD inhibited increase in
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use different receptors for entry or that different regions
of gD from BoHV-5 may be critical for entry [56]. In-
deed, a study showed that BoHV-5 gD can interact with
human nectins 1 to 4. Also, a cell type known as J1.1-2
cells, which does not express any form of nectin and is
resistant to HHV and BoHV-1 infection, is susceptible to
BoHV-5 infection, reinforcing the idea that BoHV-5 gD
can interact with a different range of receptors than
those used by BoHV-1 [34]. Replacement of BoHV-1 gD
by the homologous BoHV-5 gD confers an extended
host range to BoHV-1 and increased virulence, which,
however, does not affect the brain invasiveness of this
recombinant virus [34].
The role of gD in the initial stage of BoHV-1 and -5 in-
fection and its abundance in the viral envelope makes it a
target for the host immune system. The host immune re-
sponses to these viruses can be divided into innate re-
sponses mediated by polymorphonuclear neutrophils
(PMN), macrophages, natural-killer cells (NK-cells),
natural-killer T cells (NKT-cells) and dendritic cells (DCs),
and adaptive responses by B and T lymphocytes, which
are responsible for antibody production (which may pre-
vent infection) and cytotoxic T cell (CTL) killing (which,
together with humoral responses, aid in recovery). The
immunology of BoHV-1 infection was reviewed in 1996
[21], and very few studies have been performed to eluci-
date the immune response induced by BoHV-5 infection.
However, due to the similarities between both viruses, it is
reasonable to expect that most of what was discovered for
BoHV-1 may apply to BoHV-5 (reviewed in [8]). The first
step in an immune response to a virus infection is to avoid
the interaction between virus and permissive cells; how-
ever, during primary infection, antibodies are not available
to interfere with these interactions. Thus, the first re-
sponse of the immune system against a BoHV-1 infection
will consist of nonspecific inflammatory and cell-mediated
reactions, gD and gB being primary targets for NK-cells
[57]. The innate responses lead to adaptive immune re-
sponses later during infection. Glycoproteins gC and gD
are targets for CD8+ CTLs in bovines, and gD possesses
specific epitopes which stimulate CD4+ T-lymphocytes
[58]. Antibody responses, as mentioned, do not prevent
cell-to-cell spread and become detectable when recovery
from primary infection is underway. However, during sec-
ondary exposure they play a pivotal role in preventing in-
fection, since they are critical in neutralizing extracellular
virus and may prevent spread to neighboring animals.
Non-neutralizing antibodies may also contribute together
with PMNs, which can cause lysis of BoHV-1 infected cells
via antibody-dependent cell cytotoxicity (ADCC) [59].
Thus, it becomes clear that the major glycoproteins
are not only involved in inducing antibody that may pro-
tect the animal from disease, but also in stimulating cell-mediated responses, as they are also targets for CTLs
and ADCC. For these reasons, it is important that new
vaccine strategies against BoHV-1 and -5 focus on or in-
clude the major glycoproteins, in particular gD (reviewed
in [21]).
3. Vaccines designed with gD
3.1 Subunit vaccines
Subunit vaccines consist of one or more pure or semi-
pure antigens. To develop subunit vaccines, it is important
to identify the individual components that are involved in
protection from the pathogen. This kind of vaccine may
be produced by conventional technologies, such as purifi-
cation of the protein produced by the pathogen. To
develop a safe vaccine against BoHV-1, viral envelope gly-
coproteins, gB, gC and gD, were purified directly from
virus-infected cells and retained their antigenic activity, in-
ducing the production of neutralizing antibodies in cattle
and protection against challenge with virulent BoHV-1.
Although all three glycoproteins induced neutralizing anti-
bodies, titers were higher in the animals immunized with
gD, and these animals also had higher ADCC titers
[60,61].
While purified native glycoproteins from infected cells
retain their antigenic characteristics, this method is gener-
ally not cost-effective, so the use of recombinant DNA
technology to produce large quantities of proteins for in-
corporation into vaccines may fulfill the safety and eco-
nomic requirements. Production of recombinant BoHV-1
gD has been achieved in several expression systems, from
prokaryotes to eukaryotes. Prokaryotic systems, although
possessing several advantages regarding manipulation, low
cost and the possibility to achieve high amounts of protein
production, have some disadvantages regarding the
expression of viral glycoproteins. As mentioned, the con-
formational structure of gD relies on its correct three-
dimensional folding, which at least partially is dependent
on its insertion into the endoplasmic reticulum and on the
addition of carbohydrates. Prokaryotic systems do not pos-
sess the cell machinery to perform post-translational mod-
ifications necessary for proper gD folding. This was
confirmed when BoHV-1 gD was expressed in Escherichia
coli. Despite the higher total antibody levels induced by
the E. coli-expressed recombinant gD (rgD), only a small
portion of those were capable of neutralizing the virus
[62].
As a result of the low efficacy of recombinant gD pro-
duced in prokaryotes, eukaryotic expression systems
were tested, such as yeast, mammalian, plant and insect
cells. Yeast, such as the methylotrophic Pichia pastoris,
was used as expression system for a secreted form of gD
from BoHV-1 alone, or in combination with bovine
interleukin (IL)-6 as a chimeric protein. Both recombin-
ant proteins induced neutralizing antibodies in mice
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gD from BoHV-5 in P. pastoris by removing the trans-
membrane anchor of the native gD [65]. Recombinant
BoHV-5 gD when formulated with oil-based adjuvants
induced neutralizing antibodies in mice [25] and bovines
(Itauá Leston Araújo, 2014 - unpublished observations)
after vaccination.
A Tobacco Mosaic Virus (TMV)-based vector (TMV-
30B) was used to express a cytoplasmic non-glycosylated
form of BoHV-1 gD in plant cells. Mice and cattle immu-
nized with an oil-based gD vaccine formulation developed
humoral and cell-mediated immune responses, and
seemed to be partially protected from disease after viral
challenge; however, no viral neutralization test was per-
formed in this trial [66]. Although yeast, plant and insect
cells were able to produce gD with some degree of authen-
ticity, most reports are based on a secreted form of
BoHV-1 gD (also called tgD) produced in MDBK cells
under the control of an inducible bovine heat shock 70A
gene promoter (HSP70 promoter) [67]. High levels of
BoHV-1 gD, when constitutively expressed in MDBK cells,
proved toxic to cells, stable cell lines being established
only when the BoHV-1 gD was placed under the control
of an inducible promoter [35] or when expressed at basal
levels [68]. This problem was solved by removing the
transmembrane anchor, resulting in a secreted version of
gD with equal immunogenicity to full-length gD [69,70].
BoHV-1 tgD has been combined with several adju-
vants and co-adjuvants and administered by different
routes to induce systemic and mucosal immune re-
sponses. One of the most effective approaches seems to
be the incorporation of CpG-containing oligodeoxynu-
cleotides (ODN) in vaccine formulations with classical
adjuvants. Cell-mediated immune responses are critical
for protection from several pathogens, and, although all
currently licensed vaccines are efficient at inducing anti-
body responses, only modified live vaccines efficiently
induce cell-mediated immunity. However, experimental
subunit vaccines when formulated with the appropriate
adjuvants may induce cell-mediated immune responses
due to cross-presentation. Formulation of tgD with alum
and CpG ODN (or even tgD with CpG ODN alone) in-
duced strong neutralizing antibodies and cell-mediated
immune responses in calves, resulting in fast recovery
from BoHV-1 challenge [71]. The incorporation of CpG
ODN in oil-based vaccines against BoHV-1 also resulted
in strong Th1-type immune responses, with an increase
in production of interferon-gamma (IFN-γ), or balanced
immune responses, in contrast to the immune responses
induced by the conventional adjuvants alone, which
were Th2-biased in mice [72]. On the other hand, with
respect to experimental vaccines against BoHV-5, mixed
Th1/Th2 immune responses were observed when we
vaccinated mice with recombinant BoHV-5 gDformulated only with oil-based adjuvant. This resulted in
induction of IFN-γ as well as pro-inflammatory cyto-
kines, such as IL-17 and granulocyte-macrophage
colony-stimulating factor (GM-CSF) [25]. More import-
antly, BoHV-1 tgD formulated with both CpG ODN and
Emulsigen elicited a more balanced immune response,
and higher levels of virus neutralizing antibodies, com-
pared to BoHV-1 tgD adjuvanted with Emulsigen, as
well as full protection from disease after BoHV-1 chal-
lenge [73]. Interestingly, the formulation of BoHV-1 tgD
with Emulsigen and CpG ODN also induced robust, bal-
anced immune responses in newborn calves, which were
almost completely protected from disease after a high-
dose BoHV-1 challenge [74]. The addition of CpG ODN
to the tgD-Emulsigen formulation allowed us to reduce
the antigen dose 5- to 25-fold without decrease in the
antibody titers induced in calves (Figure 2); thus, the co-
adjuvanting with CpG ODN resulted in antigen sparing
which is important for potentially making a gD subunit
vaccine commercially viable.
3.2 DNA vaccines
The demonstration that direct transfection in vivo with
plasmid DNA could be used to express foreign proteins
and thereby induce both humoral and cell-mediated im-
mune responses in a variety of murine and primate dis-
ease models has provided a new opportunity to develop
non-replicating vaccines that induce balanced immune
responses. Immunization by direct transfection in vivo
with plasmid DNA encoding protective antigens is an ef-
ficient means of eliciting CD8+ CTLs, which means that
protein antigens produced by DNA vaccination gain ac-
cess to pathways of antigen presentation via Class I
MHC molecules, a system that is most frequently uti-
lized by live attenuated virus vaccines (reviewed by
Donnelly et al. [75] and Gurunathan et al. [76]). DNA
vaccines attracted attention owing to the immune re-
sponses generated, which closely resemble those induced
by natural infection, due to endogenous production of
viral proteins and glycoproteins [77].
The earliest DNA vaccine developed against BoHV-1
was engineered with a pRSV plasmid, which contains
transcriptional control sequences from rous sarcoma
virus, and is functional in a wide range of animal cell
types [78]. Three glycoproteins were tested individually
in mice, and neutralization titers specific for gD after
intramuscular injection were higher than those obtained
for gB or gC [79]. However, intramuscular immunization
of cattle with a gD DNA vaccine resulted in low humoral
immune responses. Improved immune responses were
achieved by replacing the RSV promoter with the Hu-
man cytomegalovirus (HCMV) immediate-early pro-
moter/enhancer, expressing the secreted form (tgD) and
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Figure 2 IgG gD-specific titers in calves vaccinated with different doses and formulations of BoHV-1 tgD. tgD was formulated with 15%
(v/v) of Emulsigen in the absence or presence of 250 μg of CpG ODN. Antibody titers were determined by enzyme-linked immunosorbent assay
(ELISA). The procedures were performed in accordance with the standards stipulated by the Canadian Council on Animal Care.
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the induction of tgD-specific antibody titers and high
numbers of IFN-γ-secreting cells, sufficient to provide
significant protection from clinical signs after BoHV-1
challenge [80]. In contrast, in another study in 2004
[81], a DNA vaccine encoding a truncated form of
BoHV-1 gD was tested in calves through three different
routes: intramuscular, intradermal and intranasal. Only
intramuscular injection resulted in neutralizing anti-
bodies and in early clearance of viral shedding after chal-
lenge. However, in mice a plasmid encoding secreted
forms of gD and gB and administrated by intranasal
route induced high neutralizing antibody titers [82].
Incorporation of multiple copies of CpG motif into a
tgD-encoding plasmid also resulted in lymphocyte pro-
liferation and cell-mediated immunity and, following
BoHV-1 challenge, high neutralization titers and lower
levels of virus shedding, but no difference in clinical
symptoms [83]. Plasmid encoding tgD linked to bovine
CD154 administered by intradermal immunization was
able to bind CD40-expressing DCs present in the skin;
however, no enhanced immune response or protection
from disease was induced by tgD-CD154, when com-
pared to tgD alone [84]. One of the currently more
promising approaches to improve the transfection effi-
ciency of plasmids in vivo, and thus the level of antigen
expression, is delivery by electroporation. We demon-
strated that by using a TriGridTM Delivery System for
intramuscular delivery (Ichor Medical Systems), a bovine
viral diarrhea virus (BVDV) vaccine induced balanced
immune responses and close to complete protection
from clinical disease following challenge with BVDV-2
[85]. As electroporation is being extensively tested inhumans and the equipment adapted for easy use, this
might be an approach that can be evaluated for delivery
of plasmids encoding gD from BoHV-1 and BoHV-5.
3.3 Vectored vaccines
Vectored vaccines are also expected to induce balanced
immune responses once the cell endogenously produces
the protective antigen. One of the main advantages of
this kind of vaccine is the potential to deliver the antigen
directly to the mucosal surfaces and also, the ability to
induce humoral and cell-mediated immune responses.
Due to the ability of bovine adenovirus 3 (BAV-3) to
replicate in the respiratory tract of cattle while produ-
cing mild or no clinical symptoms, and to grow to high
titers in cell culture [86], BAV-3 expressing gD was used
to immunize cattle. Intranasal immunization with a
replication-competent BAV-3 expressing full-length gD
or tgD produced gD-specific immune responses, includ-
ing IgA in the nasal secretions. However, although ani-
mals were partially protected after BoHV-1 challenge,
the magnitude of the IgA response was not sufficient to
eliminate BoHV-1 shedding [87]. The same pattern of
response was observed by immunization of cattle
through intratracheal/subcutaneous routes [88].
Human adenovirus 5 (HAdV-5) has also been used as
viral vector to deliver BoHV-1 glycoproteins. Replication-
defective HAdV-5 expressing gC or gD under the control
of the HCMV immediate-early promoter/enhancer or hu-
man desmin gene 5′regulatory region (DESM) promoter
was used to induce immune responses in a rabbit model.
A single intranasal immunization with the HAdV-5 ex-
pressing gD alone or in combination with HAdV-5 ex-
pressing gC, both under the control of the CMV
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ited by gD being much higher than those induced by gC.
The same was observed after intramuscular administration
of HAdV-5 expressing gD under the control of the DESM
promoter; however, the neutralizing antibodies were lower
than those induced by intranasal immunization [89]. This
vector expressing gC and gD induced virus neutralizing
antibodies and clinically protected cattle from BoHV-1
challenge after intranasal administration [89]. The same
vector construct was further used in combination with
glycol chitosan, also demonstrating protection against
challenge [90]. No cell-mediated immune responses were
evaluated in these trials. A summary of the principal re-
sults of vaccines formulated with gD from BoHV-1 and
BoHV-5 is presented in Table 1.
The gD from another alphaherpesvirus, the Caprine
herpesvirus 1 (CpHV-1), has recently been expressed in
the genome of a gammaherpesvirus, Bovine herpesvirus
4 (BoHV-4). Subcutaneous administration of the engi-
neered BoHV-4 carrying the CpHV-1 gD gene protected
animals from clinical signs and reduced viral shedding
after challenge [91]. Although this reinforces the success
of the gD vaccines in stimulating the host immune sys-
tem, protecting from clinical signs and diminishing viral
shedding, these results have not always been achieved
with other alphaherpesviruses, as was observed for
HHV-1 and HHV-2.
When gD of both HHV-1 and HHV-2 as vaccine anti-
gen was tested in animal models, this glycoproteinTable 1 Principal results obtained with BoHV-1 and BoHV-5 g
Vaccine Virus Expression Adjuvant Rout
system
Subunit BoHV-1 Native gD Avridine i.m
BoHV-1 E. coli Avridine i.m
BoHV-1 P. pastoris Oil i.m
BoHV-5 P. pastoris Oil i.m
BoHV-1 MDBK Oil i.m
BoHV-1 MDBK CpG; Alum i.m
BoHV-1 MDBK CpG; Oil s.
BoHV-1 Plant cellsa Oil i.p., s.
DNA BoHV-1 pRSV n/a i.m
BoHV-1 HCMV n/a i.d
BoHV-1 HCMV n/a i.m
BoHV-1 HCMV CpG i.d
Vectored BoHV-1 BAV-3 n/a i.
BoHV-1 HAd5 n/a i.
a = achieved with a Tobacco Mosaic Virus (TMV)-based vector.
++ =Weak neutralizing antibodies or cell-mediate response.
++++ = Strong neutralizing antibodies or cell-mediate response.
n/a = Data not available.
xx = Partial protection.
xxxx = Total protection.indeed induced immune responses capable of mediating
clinical protection and reduction of viral shedding
[92,93]. In a prophylactic trial with guinea pigs HHV-1
gD expressed in mammalian cells induced neutralizing
antibodies to both HHV-1 and HHV-2, protecting from
clinical symptoms after challenge by intravaginal infec-
tion with HHV-2 [92]. However, trials performed in
humans did not demonstrate similar results (reviewed in
2003 by Koelle and Corey [94]). The HHV-2 gD com-
bined with gB and the adjuvant MF59, although capable
of eliciting HHV-2-specific neutralizing antibodies, only
produced partial and transient clinical protection from
HHV-2 [95]. In trials using HHV-2 gD combined with
alum and 3′-O’deacylated-monophosphoryl lipid A
(MPL) the vaccine was well tolerated and protected
women with no preexisting HHV antibodies from dis-
ease, but failed to protect men and did not add to the
protection provided by previous HHV-1 infection in
women [96,97].
In 2012, these trials were repeated indicating that the
vaccine was not efficacious with regard to protection
against genital disease caused by either HHV-1 and HHV-
2 after two administrations, whereas three doses were asso-
ciated with efficacy against HHV-1, but not HHV-2 [98].
Subsequent studies correlated the administration of the
vaccine with protection from HHV-1 disease, attributing
these results to the homology between the region of HHV-
2 gD used in the vaccine with the corresponding region of
HHV-1 gD. Although the vaccine stimulated neutralizingD vaccines
e Immune Resp. Protection Ref.
Humoral Cellular
. ++++ n/a xxxx [60,61]
. ++ n/a xx [62]
. ++++ ++ n/a [63,64]
. ++++ ++ n/a [25]
. ++++ ++ xx [69,70]
. ++++ ++++ xxxx [71]
c. ++++ ++++ xxxx [72]
c, i.m. n/a n/a xx [66]
. ++++ n/a xx [79]
. ++++ ++++ xxxx [80]
. ++++ ++++ xxxx [82]
. ++ ++++ xx [83]
n ++ ++++ xx [87,88]
n ++ n/a xxxx [89,90]
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caused by HHV-2, which, as suggested by the authors, may
indicate a need to develop new vaccine strategies to stimu-
late higher antibody titers against HHV-2 [99].
Recent trials with HHV-2 gD also implicate the need
to stimulate proper cell-mediated immunity for protec-
tion from disease caused by HHV. Combination of
HHV-2 gD with immediate-early proteins, such as
ICP27 or ICP4 that stimulate stronger T cell immunity,
enhanced the level of clinical protection when compared
to gD alone, when tested in mice or guinea pigs followed
by challenge with HHV-2 [93,100].
4. Conclusions
Glycoprotein D homologues of alphaherpesviruses play a
major role in viral interactions with permissive cells and
are very immunogenic. For these reasons, gD has been
employed in vaccine candidates over the last decades
and may still be applied as long as new immunization
strategies are developed. Knowing its characteristics and
what has been achieved so far with this glycoprotein is
important to develop further approaches to minimize
economic losses caused by BoHV-1 and BoHV-5 in cat-
tle worldwide. Subunit gD vaccines have been shown to
be very efficacious, but have the drawback of being ex-
pensive for use in cattle. This may be overcome by
formulation with effective adjuvants, in particular com-
binations like CpG ODN and Emulsigen, such that the
antigen dose can be reduced making the vaccine more
affordable. The reports presented in the literature so far
indicate that, although DNA vaccines encoding gD are
suitable for the induction of cell-mediated immune re-
sponses, improvements are still needed to achieve a bal-
anced response where both cell-mediated and humoral
immune responses are present. This means that better
delivery systems need to be developed to improve the
transfection efficiency in vivo and level of antigen ex-
pression in the vaccinated animals. Vectored gD vac-
cines are particularly promising for induction of mucosal
immunity, but also need to be improved. Virus neutraliz-
ing antibodies constitute one of the most important cor-
relates of clinical protection for BoHV-1 and BoHV-5.
This suggests that at this stage a gD subunit vaccine for-
mulated with an adjuvant that promotes a balanced im-
mune response best fulfills the requirements to induce
strong humoral and cell-mediated immunity.
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